ERBB2 and neoplasm: These cells overexpress a variety of tumor-associated antigens, including HER2/neu, TRP-2, AIM-2, gp100, MAGE1, and IL13Rα2 [40–45], and the presence of these cells is consistent with poor response to traditional GBM therapy [46–48].